About Kura Oncology, Inc.
Our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives.
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- San Diego, California
- Founded
- 2014
- Company type
- Public Company
Kura Oncology is a commercial-stage biopharmaceutical company committed to discovering and developing innovative precision medicines to help patients with cancer lead better, longer lives.
Through our deep understanding of cancer biology and decades of experience in precision oncology, we are studying the underlying causes of treatment resistance. This enables us to design smart combination regimens with other cancer therapies to target tumors from multiple directions, with the goal of improving long-term clinical benefit.
Kura developed and is commercializing KOMZIFTI™ (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition.
For additional information, please visit Kura’s website at www.kuraoncology.com.
Specialties
- Oncology
- Precision Medicine
- Targeted Therapeutics
- Biomarkers
- Solid Tumors
- Blood Cancers
- and Research and Development
Company locations
4930 Directors Pl, Suite 500, San Diego, California 92121, US
2 Seaport Ln, Suite 8A, Boston, Massachusetts 02210, US
Locations listed on the company profile. These may include offices outside Canada, and not every location is hiring.
On LinkedIn
- Followers
- 38,269
- People linked to this company
- 322
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.